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Association of Noninvasive Oxygenation Strategies With All-Cause
Mortality in Adults With Acute Hypoxemic Respiratory Failure
A Systematic Review and Meta-analysis
Bruno L. Ferreyro, MD; Federico Angriman, MD, MPH; Laveena Munshi, MD, MSc; Lorenzo Del Sorbo, MD;
Niall D. Ferguson, MD, MSc; Bram Rochwerg, MD, MSc; Michelle J. Ryu, MLIS; Refik Saskin, MSc;
Hannah Wunsch, MD, MSc; Bruno R. da Costa, MSc, PhD; Damon C. Scales, MD, PhD
IMPORTANCE Treatment with noninvasive oxygenation strategies such as noninvasive
ventilation and high-flow nasal oxygen may be more effective than standard oxygen therapy
alone in patients with acute hypoxemic respiratory failure.
OBJECTIVE To compare the association of noninvasive oxygenation strategies with mortality
and endotracheal intubation in adults with acute hypoxemic respiratory failure.
DATA SOURCES The following bibliographic databases were searched from inception until
April 2020: MEDLINE, Embase, PubMed, Cochrane Central Register of Controlled Trials,
CINAHL, Web of Science, and LILACS. No limits were applied to language, publication year,
sex, or race.
STUDY SELECTION Randomized clinical trials enrolling adult participants with acute hypoxemic
respiratory failure comparing high-flow nasal oxygen, face mask noninvasive ventilation,
helmet noninvasive ventilation, or standard oxygen therapy.
DATA EXTRACTION AND SYNTHESIS Two reviewers independently extracted individual study
data and evaluated studies for risk of bias using the Cochrane Risk of Bias tool. Network
meta-analyses using a bayesian framework to derive risk ratios (RRs) and risk differences
along with 95% credible intervals (CrIs) were conducted. GRADE methodology was used to
rate the certainty in findings.
MAIN OUTCOMES AND MEASURES The primary outcome was all-cause mortality up to 90 days.
A secondary outcome was endotracheal intubation up to 30 days.
RESULTS Twenty-five randomized clinical trials (3804 participants) were included. Compared
with standard oxygen, treatment with helmet noninvasive ventilation (RR, 0.40 [95% CrI,
0.24-0.63]; absolute risk difference, −0.19 [95% CrI, −0.37 to −0.09]; low certainty) and face
mask noninvasive ventilation (RR, 0.83 [95% CrI, 0.68-0.99]; absolute risk difference, −0.06
[95% CrI, −0.15 to −0.01]; moderate certainty) were associated with a lower risk of mortality
(21 studies [3370 patients]). Helmet noninvasive ventilation (RR, 0.26 [95% CrI, 0.14-0.46];
absolute risk difference, −0.32 [95% CrI, −0.60 to −0.16]; low certainty), face mask
noninvasive ventilation (RR, 0.76 [95% CrI, 0.62-0.90]; absolute risk difference, −0.12 [95%
CrI, −0.25 to −0.05]; moderate certainty) and high-flow nasal oxygen (RR, 0.76 [95% CrI,
0.55-0.99]; absolute risk difference, −0.11 [95% CrI, −0.27 to −0.01]; moderate certainty)
were associated with lower risk of endotracheal intubation (25 studies [3804 patients]).
The risk of bias due to lack of blinding for intubation was deemed high.
CONCLUSIONS AND RELEVANCE In this network meta-analysis of trials of adult patients with
acute hypoxemic respiratory failure, treatment with noninvasive oxygenation strategies
compared with standard oxygen therapy was associated with lower risk of death. Further
research is needed to better understand the relative benefits of each strategy.
JAMA. 2020;324(1):57-67. doi:10.1001/jama.2020.9524
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A cute hypoxemic respiratory failure is among the lead-ing causes of intensive care unit admission in adult pa-tients, often leading to endotracheal intubation and in-
vasive mechanical ventilation.1 The current coronavirus disease
2019 (COVID-19) pandemic has further highlighted the impor-
tance of understanding the best approach to providing respi-
ratory support for patients with respiratory failure. Invasive
mechanical ventilation is associated with severe adverse
events,2 and avoiding unnecessary endotracheal intubation re-
mains a major goal in the management of patients with acute
hypoxemic respiratory failure.3 Multiple noninvasive oxygen-
ation strategies have been developed to support oxygenation
and ventilation that may lead to a reduced risk of endotra-
cheal intubation and mortality. However, it remains unclear
which of these is most effective.4
Standard oxygen therapy, typically at flow rates of less
than 15 L/min, has been the conventional approach to deliv-
ering supplemental oxygen to patients with acute hypoxemic
respiratory failure. Alternatively, noninvasive ventilation
using either a face mask or helmet interface has been pro-
moted to reduce the risk of endotracheal intubation. Oxygen
delivery at high flow via nasal cannula has been gaining
acceptance because of the ability to more closely match a
patient’s inspiratory demand in the setting of hypoxemia.5
Randomized clinical trials (RCTs) comparing the effective-
ness of noninvasive ventilation or high-flow nasal oxygen
with standard oxygen therapy have produced conflicting
results.6-12 Patients in the control groups in most of these
trials received standard oxygen therapy, and there have been
few head-to-head comparisons of the other different nonin-
vasive oxygenation modalities.7,11 Moreover, most meta-
analyses have been limited to traditional pairwise compari-
sons and therefore have not combined direct and indirect
evidence for all potential comparisons.13-16
To provide additional clinical information, a network meta-
analysis was conducted to compare the association of differ-
ent noninvasive oxygenation strategies with mortality and re-
ceipt of endotracheal intubation in adult patients with acute
hypoxemic respiratory failure.
Methods
This review has been conducted in accordance with the
Preferred Reporting Items for Systematic Review and
Meta-analysis Protocols statement extension for network
meta-analysis.17,18 The protocol was registered in the Interna-
tional Prospective Register of Systematic Reviews (PROSPERO;
CRD42019121755) and has been published.19 No institutional
review board approval was required because all study data had
been published previously and this study did not include in-
dividual patient data.
Eligibility Criteria, Literature Search, and Study Selection
A systematic literature search was conducted through April
2020 to identify RCTs enrolling adult patients (>18 years of
age) with acute hypoxemic respiratory failure comparing
high-flow nasal oxygen, face mask noninvasive ventilation,
helmet noninvasive ventilation, or standard oxygen therapy
and evaluating 1 or both of the 2 key outcomes of mortality
or endotracheal intubation. Studies that were primarily
focused on the treatment of acute exacerbations of chronic
obstructive pulmonary disease (ie, >50% of the study popu-
lation) or congestive heart failure (ie, >50% of the study
population) and those evaluating noninvasive oxygen strat-
egies in the immediate postextubation period and after
major cardiovascular surgery were excluded. The rationale
for excluding studies primarily enrolling these patients was
based on the established efficacy of noninvasive ventilation
for these conditions.20,21 However, we anticipated that
some included randomized studies would also include
patients with congestive heart failure and chronic obstruc-
tive pulmonary disease, given that the etiology of acute
respiratory failure is often unclear at presentation or may
have an acute on chronic component.
The following electronic bibliographic databases were
searched from inception until April 2020 using a comprehen-
sive search strategy developed by an information specialist:
Ovid MEDLINE, Ovid Embase, PubMed (non-MEDLINE
records only), Ovid Evidence-Based Medicine Reviews–
Cochrane Central Register of Controlled Trials, EBSCO
CINAHL Complete, Web of Science, and LILACS. The search
also included ClinicalTrials.gov, the World Health Organiza-
tion International Clinical Trials Registry Platform, and the
International Standard Randomized Controlled Trial Number
Registry (ISRCTN) for all registered clinical trials and RCTs.
The search strategy was structured according to the Peer
Review of Electronic Search Strategies (PRESS) 2015
guidelines.22 A validated search filter for RCTs from the
Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0, Section 6.4.11, was used to screen Ovid
MEDLINE, Embase, and PubMed. A pretested search filter for
RCTs from the Scottish Intercollegiate Guidelines Network
was used to screen CINAHL Complete and Web of Science.
No limits were applied to language, sex, or race.
The full texts of all articles identified as relevant during
the title and abstract screening stage were obtained and re-
viewed. The comprehensive search strategy and detailed in-
clusion and exclusion criteria are described in eAppendix 1
in the Supplement.
Key Points
Question What are the associations between noninvasive
oxygenation strategies and outcomes among adults with acute
hypoxemic respiratory failure?
Findings In this systematic review and network meta-analysis
that included 25 studies and 3804 patients with acute hypoxemic
respiratory failure, compared with standard oxygen therapy there
was a statistically significant lower risk of death with helmet
noninvasive ventilation (risk ratio, 0.40) and face mask
noninvasive ventilation (risk ratio, 0.83).
Meaning Noninvasive oxygenation strategies compared with
standard oxygen therapy were significantly associated with lower
risk of death.
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Outcomes
The primary outcome was all-cause mortality, measured at the
longest time point reported in the first 90 days after random-
ization. The secondary outcome was endotracheal intuba-
tion, measured at the longest time point reported up to 30 days.
Additional secondary outcomes included patient comfort, dys-
pnea scores, intensive care unit and hospital lengths of stay,
and 6-month mortality.
Data Extraction, Risk of Bias, and GRADE Certainty
Assessment
Two reviewers (B.L.F. and F.A.) independently extracted
individual study data and evaluated studies for risk of bias
using a previously piloted standardized form and the Coch-
rane Risk of Bias tool for RCTs.23 The following domains of
each of the primary studies were assessed: random sequence
generation, allocation concealment, blinding of study partici-
pants, incomplete outcome data, selective reporting, and
other biases. Based on these domains, the overall risk of bias
for each included study was assessed. The certainty of each
direct, indirect, and network meta-analysis estimate was
estimated based on the 4-step approach suggested by the
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) Working Group (ie, high, moderate, low,
and very low certainty).24 In the presence of incoherence (ie,
differences between direct and indirect evidence), the lower
certainty of the 2 assessments was assigned to the corre-
sponding network estimate.24
Statistical Analysis
A series of pairwise conventional meta-analyses were per-
formed with random-effects models to assess for direct asso-
ciations between interventions and study outcomes. Net-
work meta-analyses using bayesian random-effects models
(log-link, binomial likelihood) were conducted to derive head-
to-head treatment estimates comparing all interventions.
Analyses were based on Markov chain Monte Carlo methods
using minimally informative treatment effect estimates and
informative prior distributions for heterogeneity estimates, fol-
lowing the approach suggested by Turner et al.25
Although these prior distributions were derived in the log
odds scale, it was expected that these would be wide enough
to cover possible values in the log relative risk scale. Correc-
tion of the treatment associations for multigroup trials was
applied.26 Further details on the model specification are in eAp-
pendix 2 in the Supplement. Pairwise and network risk ratios
(RRs) were derived, estimating summary estimates from the
medians and corresponding 95% credible intervals (CrIs) from
the 2.5 and 97.5 percentiles of the posterior distribution. In ad-
dition to relative associations, bayesian analyses were used to
produce risk differences and 95% CrIs between treatment
groups. Prior distributions for event rates of intubation and all-
cause mortality in the standard oxygen therapy group were de-
rived from the data and from previous literature.27 The prob-
ability for each treatment to obtain each possible rank
(probability of being best, second best, etc) was also
estimated.28 Specifically, in the bayesian framework and in
each Markov chain Monte Carlo cycle, each treatment was
ranked according to the estimated effect size. The proportion
of cycles in which a treatment ranks first out of the total turns
into the probability of being first, second, and so forth.29
Heterogeneity in treatment effects between studies was
quantified using the posterior distribution τ2. Incoherence
between direct and indirect comparisons was estimated
using the node-splitting approach contrasting estimates from
both direct and indirect evidence.30,31 Model convergence
was assessed using the Brooks-Gelman-Rubin diagnostic,
trace plots, and autocorrelation plots. Goodness of fit was
assessed by comparing the mean residual deviance with the
number of contributing data points. Statistical significance
was defined as 95% CrIs that did not include the value 1.0. All
analyses were performed in R version 3.6 (R Foundation;
packages meta, gemtc, coda, pcnetmeta, and rjags) using Just
Another Gibbs Sampler (JAGS) version 4.3.0 and OpenBUGS.
Sensitivity Analyses
Several sensitivity analyses were performed to assess the ro-
bustness of the pooled RRs for the main outcomes. These analy-
ses excluded studies that enrolled any patient with acute ex-
acerbation of chronic obstructive pulmonary disease or
congestive heart failure, studies that enrolled postoperative
patients, and studies that included patients with less severe
respiratory failure (mean partial pressure of arterial oxygen
[PaO2] to fraction of inspired oxygen [FIO2] ratio >200). Be-
cause there was variability in the timing of reporting of mor-
tality, the analysis of the primary outcome was limited to stud-
ies that reported mortality at hospital discharge. An analysis
restricted to studies that included at least 50% of immuno-
compromised patients (ie, >50% of patients with hemato-
logic malignancies, solid tumors with active chemotherapy,
treatment with immunosuppressant drugs, or solid organ trans-
plants) was also conducted. Furthermore, to assess the effect
of study quality, an analysis restricted to studies with the low-
est risk of bias was performed. In addition, to assess the ro-
bustness of the findings, the main analyses were refitted using
noninformative priors for heterogeneity and also using mod-
erately enthusiastic priors for treatment effects for high-flow
nasal oxygen and skeptical priors for face mask noninvasive
ventilation, based on measures of association and distribu-
tions obtained from recent evidence.7,27,32 These latter sensi-
tivity analyses were intended to account for a subgroup of cli-
nicians who may have greater confidence in high-flow nasal
oxygen compared with face mask noninvasive ventilation. De-
tails are in eAppendix 2 in the Supplement. In addition, we per-
formed post hoc sensitivity analyses to explore sources of in-
coherence when this was present.
Results
The search strategy identified 5246 records, including 25
RCTs (3804 participants; range, 30-776 participants) that
were eligible for inclusion (Figure 1). Included trials evalu-
ated 4 different interventions, and these included 5 of 6
potential head-to-head comparisons. Specifically, 13 trials
compared face mask noninvasive ventilation with standard
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oxygen therapy, 4 trials compared high-flow nasal oxygen
with standard oxygen therapy, 2 trials compared face mask
noninvasive ventilation with high-flow nasal oxygen, 1 trial
compared face mask with helmet noninvasive ventilation,
and 4 trials compared helmet noninvasive ventilation with
standard oxygen therapy (Table and Figure 2). In addition, a
3-group study directly compared face mask noninvasive ven-
tilation with high-flow nasal oxygen and also with standard
oxygen therapy (therefore, there were a total of 27 compari-
sons for 25 RCTs).7 No studies compared high-flow nasal oxy-
gen with helmet noninvasive ventilation.
The Table describes the main study and cohort character-
istics of the included trials. Mean age at randomization ranged
from 30 to 75 years, mean PaO2:FIO2 ratio was predominantly
below 200 (14 trials [56%]), and more than half of the trials
(14 trials [56%]) allowed inclusion of immunocompromised pa-
tients. Community-acquired pneumonia was the most com-
mon cause of acute hypoxemic respiratory failure in 16 trials
(64%). Pairwise comparisons are shown in eFigure 1 in the
Supplement.
Noninvasive Oxygenation Strategies and Risk of Mortality
Twenty-one trials (3370 patients) were included in the mor-
tality analysis, of which 1 (47 patients) did not report any deaths
in any of the treatment groups.37 Despite the absence of blind-
ing, the risk of bias was determined to be low for the outcome
of mortality in most (16 trials [76%]) of these trials (eTable 1 in
the Supplement).
Using standard oxygen as the reference, helmet noninva-
sive ventilation (RR, 0.40 [95% CrI, 0.24-0.63]; absolute risk
difference, −0.19 [95% CrI, −0.37 to −0.09]; low certainty) and
face mask noninvasive ventilation (RR, 0.83 [95% CrI, 0.68-
0.99]; absolute risk difference, −0.06 [95% CrI, −0.15 to −0.01];
moderate certainty) were significantly associated with a lower
risk of mortality. High-flow nasal oxygen (RR, 0.87 [95% CrI,
0.62-1.15]; absolute risk difference, −0.04 [95% CrI, −0.15 to
0.04]; moderate certainty) was not associated with a statisti-
cally significant lower risk of mortality compared with stan-
dard oxygen therapy. Figure 3A and eFigure 2 in the
Supplement show the results for all potential comparisons in
the network meta-analysis for all-cause mortality. Helmet non-
invasive ventilation was also associated with a significant de-
crease in mortality compared with high-flow nasal oxygen (RR,
0.46 [95% CrI, 0.26-0.80]; absolute risk difference, −0.15 [95%
CrI, −0.34 to −0.05]; low certainty) and face mask noninva-
sive ventilation (RR, 0.48 [95% CrI, 0.29-0.76]; absolute risk
difference, −0.13 [95% CrI, −0.27 to −0.05]; low certainty).
There was no significant difference in the association with mor-
tality when comparing face mask noninvasive ventilation with
high-flow nasal oxygen (RR, 0.95 [95% CrI, 0.69-1.37]; abso-
lute risk difference, −0.02 [95% CrI, −0.14 to −0.07]; low cer-
tainty). Incoherence between direct and indirect RRs was ob-
served for the comparison of face mask noninvasive ventilation
vs high-flow nasal oxygen (eFigure 3 in the Supplement). The
probability of being best in reducing all-cause mortality among
all possible interventions was higher for helmet noninvasive
Figure 1. Summary of Study Retrieval and Identification for Network Meta-analysis
5246 Records identified through
database search
1 Additional record identified
through reference search
721 Duplicate records excluded
4481 Records excluded
20 Articles excluded
3 Crossover studies
2 Not randomized trials
2 Had inadequate controls
2 Had duplicate data
1 Did not measure any outcome
of interest
10 Included >50% of patients with
chronic obstructive pulmonary
disease, heart failure, or thoracic surgery
25 Randomized clinical trials included (3804 participants)
13 Face mask vs standard oxygen (1521 participants)
4 High-flow vs standard oxygen (1279 participants)
4 Helmet vs standard oxygen (377 participants)
2 Face mask vs high-flow (234 participants)
1 High-flow vs face mask vs standard oxygen
(310 participants)
1 Helmet vs face mask (83 participants)
4526 Records screened
45 Full-text articles assessed for eligibility
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ventilation, followed by face mask noninvasive ventilation,
high-flow nasal oxygen, and standard oxygen therapy (eFig-
ure 4 in the Supplement). eTable 2 in the Supplement sum-
marizes the evidence grading for all comparisons (direct, in-
direct, and network estimates) and for both study outcomes.
Noninvasive Oxygenation Strategies and Risk
of Endotracheal Intubation
Twenty-five RCTs (3804 patients) were included in the analy-
sis of endotracheal intubation, of which 1 RCT (47 patients) did
not report any intubation events in any of the treatment
groups.37 All studies were unblinded for this outcome, and the
risk of bias for this outcome was assessed as high due to po-
tential cointerventions and variable criteria for endotracheal
intubation between groups. The overall risk of bias assessed
across all domains was deemed to be high for 7 (28%) and un-
clear for 18 (72%) of the 25 trials included (eTable 3 in the
Supplement).
Helmet noninvasive ventilation (RR, 0.26 [95% CrI, 0.14-
0.46]; absolute risk difference, −0.32 [95% CrI, −0.60 to −0.16];
low certainty), face mask noninvasive ventilation (RR, 0.76
[95% CrI, 0.62-0.90]; absolute risk difference, −0.12 [95% CrI,
−0.25 to −0.05]; moderate certainty), and high-flow nasal oxy-
gen (RR, 0.76 [95% CrI, 0.55-0.99]; absolute risk difference,
−0.11 [95% CrI, −0.27 to −0.01]; moderate certainty) were as-
sociated with a lower risk of endotracheal intubation com-
pared with standard oxygen therapy (Figure 3B and eFigure 5
in the Supplement). Helmet noninvasive ventilation was as-
sociated with decreased risk of endotracheal intubation com-
pared with high-flow nasal (RR, 0.35 [95% CrI, 0.18-0.66]; ab-
solute risk difference, −0.20 [95% CrI, −0.43 to −0.08]; low
certainty) and face mask noninvasive ventilation (RR, 0.35 [95%
CrI, 0.19-0.61]; absolute risk difference, −0.20 [95% CrI, −0.40
to −0.09]; low certainty). No significant difference was ob-
served for the association with endotracheal intubation when
comparing face mask noninvasive ventilation and high-flow
nasal oxygen (RR, 1.01 [95% CrI, 0.74-1.38]; absolute risk dif-
ference, −0.00 [95% CrI, −0.13 to 0.10]; low certainty). There
was incoherence between the direct and indirect RRs for the
comparison of face mask noninvasive ventilation vs high-
flow nasal oxygen (eFigure 6 in the Supplement). A post hoc
sensitivity analysis demonstrated that the incoherence was
eliminated when studies that included patients with chronic
obstructive pulmonary disease and congestive heart failure and
the study by Frat et al7 were excluded (eFigure 7 in the Supple-
ment). The probability of being best in reducing risk of endo-
tracheal intubation was highest for helmet noninvasive ven-
tilation, followed by face mask noninvasive ventilation, high-
flow nasal oxygen, and standard oxygen therapy (eFigure 8 in
the Supplement). Model fit and convergence characteristics are
shown in eFigures 9 and 10 and eTable 4 in the Supplement.
Additional Secondary Outcomes
Median intensive care unit and hospital lengths of stay for
different noninvasive strategies are presented in eTable 5 in
the Supplement; no significant differences were evident
between groups. Meaningful results for prespecified second-
ary outcomes of patient comfort (reported in only 28% ofTa
bl
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studies) and dyspnea score (reported in only 16% of studies)
could not be generated because insufficient information for
all network comparisons was available. In addition, 6-month
mortality was available in only 1 study.8
Sensitivity Analyses
For the primary outcome, the observed association between
face mask noninvasive ventilation and reduced risk of mor-
tality was no longer significant when considering studies that
included only patients with more severe respiratory failure
(mean PaO2:FIO2 ratio <200), when using noninformative pri-
ors for heterogeneity, and after excluding studies that en-
rolled any patients with chronic obstructive pulmonary dis-
ease, with congestive heart failure, or who were in the
postoperative period (eTable 6 in the Supplement). However,
the association of helmet ventilation with a lower risk of mor-
tality remained significant across all sensitivity analyses. For
the secondary outcome, all noninvasive ventilation strate-
gies remained significantly associated with reduced risk of in-
tubation across multiple sensitivity analyses when com-
pared with standard oxygen therapy. Finally, the analyses
restricted to studies with low risk of bias yielded results simi-
lar to the main analysis for all comparisons (eTables 6 and 7 in
the Supplement).
The overall results were robust when the analyses consid-
ered moderately optimistic priors that high-flow nasal oxy-
gen would be associated with benefit and skeptical priors that
face mask ventilation would be associated with harm. In these
analyses, helmet noninvasive ventilation remained associ-
ated with a lower risk of endotracheal intubation and all-
cause mortality compared with standard oxygen therapy. How-
ever, face mask noninvasive ventilation was no longer
associated with a lower risk of intubation compared with stan-
dard oxygen therapy (eTables 8 and 9 in the Supplement).
Discussion
In this network meta-analysis of trials of adults with acute hy-
poxemic respiratory failure, treatment with noninvasive oxy-
genation strategies compared with standard oxygenation
therapy was associated with a lower risk of death, the primary
outcome, and endotracheal intubation, a secondary outcome.
The results of this study exhibit the potential benefit of
delivering noninvasive ventilation using a helmet interface to
patients with acute hypoxemic respiratory failure, although
the low certainty should be considered when interpreting
these results. These findings are consistent with a recent sys-
tematic review and traditional pairwise meta-analysis that
showed that use of helmet noninvasive ventilation was asso-
ciated with decreased risk of intubation and mortality com-
pared with other modalities.13 However, in addition to not
including indirect evidence, this previous study included
both randomized and observational studies and included
studies primary targeting patients with acute exacerbation of
chronic obstructive pulmonary disease. The results of this
network meta-analysis also raise the question of whether
helmet noninvasive ventilation and face mask noninvasive
ventilation should be considered distinct therapeutic inter-
ventions with potentially different physiological and clinical
effects. Physiological studies have shown that the helmet
interface decreases air leaks compared with the face mask
interface; decreased air leaks may allow for more effective
delivery of higher levels of positive end-expiratory pressure,
potentially increasing alveolar recruitment and decreasing
respiratory effort.3,52-54 Patients with acute hypoxemic respi-
ratory failure may also have better tolerance for a helmet
interface compared with other strategies, minimizing inter-
ruptions in therapy.11
Figure 2. Network Plots for the Association of Noninvasive Oxygenation Strategies With All-Cause Mortality and Intubation
All-cause mortalityA IntubationB
Face mask
noninvasive
ventilation
Helmet noninvasive ventilation
High-flow nasal oxygen
Standard
oxygen
Standard
oxygen
41
14
1664 Patients in 22 studies1034 Patients in 17 studies
877 Patients in 7 studies
229 Patients in 5 studies
Face mask
noninvasive
ventilation
Helmet noninvasive ventilation
High-flow nasal oxygen
4
31
1
14
1564 Patients in 20 studies918 Patients in 15 studies
659 Patients in 3 studies
229 Patients in 5 studies
53
Network geometry shows nodes as interventions and each head-to-head direct
comparison as lines connecting these nodes. There is no direct comparison
between high-flow nasal oxygen and helmet noninvasive ventilation for any
of the study outcomes. The size of the nodes is proportional to the number of
participants in each node. The thickness of the connecting line is proportional to
the number of randomized clinical trials in each comparison. Both network plots
include 1 study (n = 47) that did not report any event of death or intubation and
1 three-group study (face mask noninvasive ventilation, high-flow nasal oxygen,
and standard oxygen therapy). Therefore, the total number of comparisons is
higher than the number of randomized clinical trials for each outcome. Patients
may be included in multiple comparisons, and this is accounted within the
bayesian model and does not mean participants are duplicated.
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The finding that face mask noninvasive ventilation was as-
sociated with a lower rate of overall mortality and endotra-
cheal intubation when compared with standard oxygen therapy
needs to be assessed in the context of the uncertainty exist-
ing in the literature and relatively small sample size of in-
cluded studies. It is possible that this association is driven
by inclusion of patients with acute hypoxemic respiratory
failure who also have chronic obstructive pulmonary dis-
ease and/or congestive heart failure; face mask noninvasive
ventilation has been demonstrated to be helpful in these
situations.21,55-59In the sensitivity analyses excluding trials that
included such patients, the association with decreased mor-
tality was no longer observed.
Concerns regarding the safety of face mask noninvasive
ventilation for patients with acute hypoxemic respiratory fail-
ure have been raised based on associations with increased mor-
tality in large observational studies in patients with acute re-
spiratory distress syndrome.27,60 Clinicians who believe that
face mask noninvasive ventilation may be harmful for acute
hypoxemic respiratory failure might consider the sensitivity
analysis using skeptical priors, in which face mask ventila-
tion was no longer associated with a lower risk of intubation
and mortality when compared with standard oxygen therapy
and might even be associated with increased harm when com-
pared with high-flow nasal oxygen therapy. Potential mecha-
nisms for such harm include higher-than-targeted tidal vol-
umes while patients breathe spontaneously, leading to high
transpulmonary pressures and patient self-inflicted lung
injury.60,61 Although these potential harms might be espe-
cially important for face mask noninvasive ventilation, they
may be common to all noninvasive oxygenation strategies,
particularly by further delaying intubation and perpetuating
lung injury in patients with high respiratory effort.61-63 This
might be especially relevant for more severely ill patients.
Figure 3. Forest Plots for the Association of Noninvasive Oxygenation Strategies With Study Outcomes
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–0.20 (–0.40 to –0.09) 0.35 (0.19-0.61)
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A, For the primary outcome, all-cause mortality, the longest follow-up was up to
90 days. B, For the secondary outcome, intubation, the longest follow-up was
up to 30 days. All outcomes are reported as network risk ratios and absolute
risk differences with 95% credible intervals (CrIs). The certainty for each
network meta-analysis estimate was estimated based on the 4-step approach
suggested by the GRADE Working Group. Initially, each direct and indirect
comparison was rated independently using the GRADE approach (risk of bias,
inconsistency, indirectness, imprecision), and these were used to rate the
network estimate. In case of disagreement between the direct and indirect
rating, the network estimate was assigned the higher rating. In the presence of
incoherence, the network estimate was assigned the lower rating of the
direct/indirect assessment. For estimating risk ratios for the comparison of
helmet noninvasive ventilation vs high-flow nasal cannula, only indirect
evidence was used because no direct pairwise comparisons were available.
The estimated absolute risk of mortality and endotracheal intubation was 30%
and 40%, respectively, in the standard oxygen group. Between-study
heterogeneity was assessed by using the posterior distribution for τ, τ2, and the
I2 statistic. For all-cause mortality, τ = 0.17 (95% CrI, 0.056-0.23), τ2 = 0.0284
(95% Crl, 0.00317-0.0508), and I2 = 12%. For endotracheal intubation, τ = 0.21
(95% CrI, 0.07-0.27), τ2 = 0.0437 (95% Crl, 0.00554-0.0743), and I2 = 15%.
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The association between noninvasive oxygenation strategies
and lower mortality was less apparent in the sensitivity analy-
sis restricted to patients with more severe hypoxemia. Addi-
tional considerations influencing decisions to use these thera-
pies include familiarity with the specific noninvasive
oxygenation strategy, perceived patient comfort, ease of de-
ployment, and level of patient monitoring required.
The results of this study also showed a significant asso-
ciation with a lower risk of intubation but not mortality with
the use of high-flow nasal oxygen when compared with stan-
dard oxygen therapy. These findings are consistent with other
recent systematic reviews.14,15 However, the sensitivity analy-
sis using optimistic priors suggested there may still be a po-
tential benefit of high-flow nasal oxygen in reducing mortal-
ity. Overall, these discordant conclusions reinforce the need
for additional RCTs of high-flow nasal oxygen therapy to treat
acute hypoxemic respiratory failure.
Limitations
This study has several limitations. First, an assumption of the
network meta-analysis is that the individual trials enrolled
similar populations and that the intervention protocols were
also similar across different studies. The analyses demon-
strated only minimal incoherence, specifically in the compari-
son of high-flow nasal oxygen vs face mask noninvasive ven-
tilation, which could be partially explained by the influence
of 1 large trial and the partial inclusion of patients with chronic
obstructive pulmonary disease and congestive heart failure.7
Trials that predominantly targeted patients with exacerba-
tions of chronic obstructive pulmonary disease or congestive
heart failure were excluded, but several trials in this network
meta-analysis included some of these patients, potentially lead-
ing to an overestimation of the beneficial effect of noninva-
sive ventilation strategies for patients with acute hypoxemic
respiratory failure.6,39,44 However, the overall findings, in par-
ticular for endotracheal intubation, were consistent in sensi-
tivity analyses that excluded these trials.
Second, aggregated study-level covariates to conduct this
network meta-analysis were not included, and assessment of
which patient-level characteristics were associated with an in-
creased likelihood of response to any of these individual thera-
pies could not be conducted.
Third, this study included patients with a range of sever-
ity of respiratory failure (based on baseline PaO2:FIO2 ratio), rep-
resenting a source of potential intransitivity. However, the rela-
tive effects of interventions can remain consistent even in the
case of different baseline risk of the outcomes.64
Fourth, although helmet noninvasive ventilation had a
higher probability to be ranked first, these findings should be
assessed with caution. The use of rank probabilities might seem
intuitive for clinicians but does not consider the certainty of
the evidence, which was deemed to be low for comparisons
with helmet noninvasive ventilation. Indeed, the studies evalu-
ating the effectiveness of this intervention were scarce and in-
cluded a small number of participants when compared with
other strategies.29 Therefore, uncertainty remains about the
effectiveness of this treatment.
Fifth, the primary studies included in this review have the
important limitation of lack of blinding of treatment groups.
Although this is unlikely to bias assessment of the primary out-
come of all-cause mortality, it is possible that clinicians had
different thresholds to provide endotracheal intubation to pa-
tients allocated to different treatment groups (eg, helmet non-
invasive ventilation).
Sixth, another potential source of heterogeneity is that in-
cluded studies reported different follow-up times for all-
cause mortality. However, the sensitivity analyses that fo-
cused on mortality assessed at hospital or intensive care unit
discharge yielded results similar to the main analysis.
Conclusions
In this network meta-analysis of trials of adults with acute hy-
poxemic respiratory failure, treatment with noninvasive oxy-
genation strategies compared with standard oxygen therapy was
associated with lower risk of death. Further research is needed
to better understand the relative benefits of each strategy.
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